Director Corporate Strategy
Vesalius Therapeutics
Director Corporate Strategy
Vesalius Therapeutics
AI-driven drug target discovery platform
Shape strategy, partnerships, and investor engagement at a pivotal point in Vesalius's growth and clinical evolution.
Vesalius Therapeutics has built a unique AI-enabled platform to identify disease-causing biology pairing the world’s largest iPSC collection with state-of-the-art cellular models and rich phenotypic screens. The platform uses genetics as the arbiter of causality to translate human biology into therapeutic hypotheses, and generate rigorous, decision-enabling evidence for drug development programs. Vesalius has formed a strategic collaboration with GSK in Parkinson’s disease and is pursuing multiple other avenues in neurodegeneration and indications outside the CNS. We are also advancing a novel therapeutic program in Alzheimer’s disease.
Vesalius Therapeutics is seeking a highly analytical, execution-oriented Director of Corporate Development to help lead enterprise strategy, external partnering, and investor engagement. This individual will work closely with senior leadership and cross-functional teams to translate scientific, clinical, competitive, and financial information into clear strategic choices, compelling external narratives, and coordinated action.
The Director will help establish an integrated strategy, business development, and investor engagement capability as Vesalius advances its first clinical program and builds a broader pipeline. They will lead structured analyses, identify and evaluate partnership opportunities, coordinate diligence and transaction support, develop Board and investor materials, and support financing and investor engagement.
The ideal candidate combines the structured problem-solving and communication skills of a top-tier strategist with commercial judgment, strong external relationship skills, and a practical understanding of biotechnology. They are comfortable working with imperfect information, can translate complex science for business and investor audiences, and take ownership from recommendation through execution.
Corporate Strategy & Portfolio Planning
Strategic Analysis & Executive/Board Support
Business Development & Partnering
Investor Engagement & External Communications
The successful candidate will build a trusted, high-impact capability across strategy, business development, and investor relations. They will improve the quality and speed of Vesalius's most important decisions, identify and advance high-value partnerships, strengthen the company's investor narrative and engagement, raise the quality of executive and Board materials, and ensure that strategic priorities translate into coordinated action and measurable progress.
We are an equal opportunity employer. All qualified applicants will be considered for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, protected veteran status, or any other characteristic protected by law.
We recognize that great candidates often bring unique strengths without fulfilling every qualification. If you have some of the experience listed above but not all, please apply anyway. We are dedicated to building diverse and inclusive teams and look forward to learning more about your background and interest in Flagship.
At Flagship, we accept impossible missions to enable bigger leaps. Our core values guide us through uncertainty and toward lasting impact.
We are an equal opportunity employer. All qualified applicants will be considered for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, protected veteran status, or any other characteristic protected by law.
We recognize that great candidates often bring unique strengths without fulfilling every qualification. If you have some of the experience listed above but not all, please apply anyway. We are dedicated to building diverse and inclusive teams and look forward to learning more about your background and interest in Flagship.
Recruitment & Staffing Agencies: Flagship Pioneering and its affiliated Flagship Lab companies (collectively, “FSP”) do not accept unsolicited resumes from any source other than candidates. The submission of unsolicited resumes by recruitment or staffing agencies to FSP or its employees is strictly prohibited unless contacted directly by Flagship Pioneering’s internal Talent Acquisition team. Any resume submitted by an agency in the absence of a signed agreement will automatically become the property of FSP, and FSP will not owe any referral or other fees with respect thereto.
The salary range for this role is $183,000 - $231,000. Compensation for the role will depend on a number of factors, including a candidate’s qualifications, skills, competencies, and experience. Vesalius Therapeutics currently offers healthcare coverage, annual incentive program, retirement benefits and a broad range of other benefits. Compensation and benefits information is based on Vesalius Therapeutics's good faith estimate as of the date of publication and may be modified in the future.
Pay Range: 183000.0 - 231000.0 USD
AI-driven drug target discovery platform
Vesalius Therapeutics develops drugs for common diseases using its ContinuumDiscovery platform. The platform combines data science, artificial intelligence, and machine learning to identify distinct patient subgroups and the combined effects of multiple genes, then finds optimal drug targets to reverse disease in those groups. It also uses proprietary patient-derived, cell-based models to screen and characterize drug candidates. Unlike traditional approaches that treat common diseases as single conditions, Vesaliusus views them as a collection of genetically and biologically different subtypes, and it targets these unique characteristics with tailored drug development. The company aims to develop and commercialize novel therapies that address these genetic and biological differences to improve patient outcomes.
Explore more opportunities at Vesalius Therapeutics